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Abstract
Cytochrome P450 oxidoreductase (POR) is known as the sole electron donor in the metabolism of drugs by cytochrome
P450 (CYP) enzymes in human. However, little is known about the effect of polymorphic variants of POR on drug metabolic
activities of CYP3A4 and CYP2B6. In order to better understand the mechanism of the activity of CYPs affected by
polymorphic variants of POR, six full-length mutants of POR (e.g., Y181D, A287P, K49N, A115V, S244C and G413S) were
designed and then co-expressed with CYP3A4 and CYP2B6 in the baculovirus-Sf9 insect cells to determine their kinetic
parameters. Surprisingly, both mutants, Y181D and A287P in POR completely inhibited the CYP3A4 activity with
testosterone, while the catalytic activity of CYP2B6 with bupropion was reduced to approximately ,70% of wild-type
activity by Y181D and A287P mutations. In addition, the mutant K49N of POR increased the CLint (Vmax/Km) of CYP3A4 up
to more than 31% of wild-type, while it reduced the catalytic efficiency of CYP2B6 to 74% of wild-type. Moreover, CLint
values of CYP3A4-POR (A115V, G413S) were increased up to 36% and 65% of wild-type respectively. However, there were no
appreciable effects observed by the remaining two mutants of POR (i.e., A115V and G413S) on activities of CYP2B6. In
conclusion, the extent to which the catalytic activities of CYP were altered did not only depend on the specific POR
mutations but also on the isoforms of different CYP redox partners. Thereby, we proposed that the POR-mutant patients
should be carefully monitored for the activity of CYP3A4 and CYP2B6 on the prescribed medication.
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Introduction
Members of cytochrome P450 monooxygenase superfamily
(CYP) are known to catalyze the biotransformation of xenobiotics,
including therapeutic drugs, carcinogens and many other
environmental chemical compounds [1]. Cytochrome P450 3A4
(CYP3A4), the most abundant CYP isoform (up to 30% of total
CYP content), had been identified in the liver and small intestine,
and is known to play a significant role in the oxidation process of
40–50% therapeutic drugs [2,3]. On the other hand, cytochrome
P450 2B6 (CYP2B6) represents only 2%,10% of total human
hepatic complement of cytochrome P450 enzymes, which has
been identified to participate in the metabolism of many clinically
important drugs such as bupropion (antidepressant), cyclophos-
phamide (anticancer), efavirenz (antiretroviral), and propofol
(anesthetic) [4].
Apparent variation of CYPs-mediated drug metabolism could
alter therapeutic efficiency and toxicity of many drugs in clinical
treatments, which was thought to be caused by CYPs polymor-
phisms in early studies [5,6]. However, all the frequencies of
identified CYPs polymorphisms can not completely explain the
wide variation in CYPs-mediated drug metabolism [7]. In a
clinical study, it has been shown that the variations in CYP3A4-
mediated metabolism of midazolam in vivo did not correlate with
the gene polymorphism of CYP3A4, but was found associated with
cytochrome P450 oxidoreductase (POR) variant A503 V [8].
Further studies on functional characterization of the POR mutants
on warfarin in vivo revealed that, in addition to several known
factors contributing to the variations in warfarin maintenance dose
(VKORC1_1639A.G, CYP2C9*2, CYP2C9*3, CYP4F2 rs2108622,
and chronic aspirin therapy), three common POR SNPs
(2173C.A,2208C.T, and rs2868177) were also significantly
associated with variations in warfarin maintenance dose [9]. Thus,
it was suggested that CYP enzymes were not only the probable
source of genetic element to cause metabolic variation, rather
there may be some other factors such as certain functional partners
of CYP and its gene polymorphisms that may influence the drug
metabolism. Recently, few researchers have indicated that the
polymorphic variants of cytochrome P450 oxidoreductase (POR)
can influence the cytochrome P450 (CYP) mediated metabolism of
drugs [7,10,11,12]. Thereby, the mechanism underlying the
altered drug metabolism by CYPs and its functional partners
should be clearly identified.
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NP_000932.3) localized in the endoplasmic reticulum (ER) as
the sole electron donor for all microsomal CYP enzymes,
hemeoxygenase and fatty acid elongase [13,14]. Moreover, it
has been suggested that POR also participates in the metabolism
of several chemical molecules such as mitomycin C, doxorubicin,
cytochrome c, ferricyanide, menadione, dichlorophenolindophe-
nol and nitro blue tetrazolium either directly or as an electron
donor for these actual catalysts [15,16]. Targeted disruption of the
POR gene in mice providing a knockout (KO) animal model
resulted in an early embryonic lethality [17,18], while liver-specific
knockout of POR in mice lead to a significant decrease of hepatic
drug metabolic ability, and no morphological and reproductive
differences were observed between the wild-type and liver-specific
POR knockout mice [19,20], suggesting that POR may also exert
its key role in embryonic development in spite of its contributions
for drug metabolism.
NADPH-cytochrome P450 oxidoreductase (POR) catalyzes the
transfer of electrons from nicotinamide adenine dinucleotide
phosphate (NADPH), via two flavin cofactors namely, flavin
adenine dinucleotide (FAD) and flavin mononucleotide (FMN), to
various cytochrome P450s and catalyzes the one-electron reduc-
tion of many drugs and xenobiotics [7]. On the other hand, the
gene encoding human POR was found to be genetically
polymorphic: 3.1 single nucleotide polymorphisms perkilobase
were found among the 1682 alleles from 842 healthy people, and
more than 40 naturally occurring POR variants in humans with
changes of single amino acid have been identified [7,21,22]. Site-
mutagenesis studies have clearly indicated that the mutations in
the NADPH, FMN, FAD binding domains of POR inhibited the
transfer of electron from NADPH to P450, and reduced the
reduction ability of cytochrome c and CYP-mediated metabolism
[23,24,25,26,27].
In fact, the majority of studies on POR variants were initially
focused on an autosomal recessive genetic disease (formerly known
as P450 oxidoreductase deficiency) with clinical phenotypes of
ambiguous genitalia, congenital adrenal hyperplasia, skeletal
malformation, Antley-Bixler syndrome (ABS), and polycystic
ovary syndrome [28]. However, some recent studies have
attempted to identify the possibility of POR as a potential rate-
limiting step in CYP-mediated drug metabolism in vitro (reconsti-
tuted) systems, using N-terminal end-deleted CYPOR by bacterial
system (prokaryocytes) since 2008.
Miller’s group have evaluated the impact of polymorphic
variants of POR on the catalytic activity of CYP1A2 and
CYP2C19 [29] as well as the effects of genetic variants of POR
on catalytic activity and substrate-specific modulation of CYP3A4
and CYP2D6 in vitro, indicating that the activities of individual
POR mutants might probably depend on the electron recipient
and substrates [30,31].
The present study was carried out to reveal the potential role of
POR genetic variations on the CYP3A4 and CYP2B6 mediated
metabolic activities and to help set up a database about the
influence of POR genetic polymorphisms as a biomarker to
predict the POR-involved metabolic activities of clinical drugs
in vitro. In order to maintain the physiological catalytic activity of
POR and CYP as practically as possible, we have selected the
following six full-length POR missense mutations (e.g., K49N,
POR*25; A115V, POR*11; Y181D, POR*8; S244C, A287P,
POR*5; G413S). These mutations in POR (e.g., Y181D, A287P,
A115V and G413) are associated with Antley-Bixler Syndrome,
and A287P was found to be the most common POR mutation in
the European population. Missense mutation K49N is located in
the amino-terminal tail of POR which is responsible for anchoring
POR into the endoplasmic reticulum (or plasma membrane) and is
important for proper electro transfer function, similarly, S244C is
located within the hinge close to FAD and FMN domains of POR.
Therefore, we expressed these six POR missense mutations in
baculovirus/Sf9 insect cell system (i.e., eukaryotic cell), and then
co-expressed with wild-type human CYP3A4 and CYP2B6
respectively, to investigate the influence of these POR genetic
variations on the metabolic activities of CYPs (i.e., CYP 3A4 and
2B6).
Materials and Methods
Materials
Polymerase chain reaction (PCR) primers were synthesized by
Sunny Biotechnology (Shanghai, China). Restriction endonucle-
ases, DNA molecular marker, and T4 ligase were obtained from
MBI Fermentas (Amherst, NY). Site-directed Mutagenesis Kit
(Stratagene, Cambridge, UK), Cellfectin reagent, pFastBac1
vector, DH10Bac-competent cells, Grace’s medium and fetal
bovine serum were purchased from Invitrogen (Calsbad, CA).
Spodoptera frugiperda Sf9 insect cells were obtained from
Yangshengtang Company (Hainan, China). The pFastBAc-3A4
and 2B6 plasmids were kindly provided by Dr. Su Zeng (Zhejiang
University). The primary anti- histidine antibody and Peroxidase-
conjugated goat anti-mouse secondary antibody were purchased
from Abmart (Shanghai, China) and Jackson ImmunoResearch
Laboratories, Inc (Pennsylvania, USA) respectively. Testosterone
and bupropion (chemical purity .99.0%) were purchased from
National Institutes for Food and Drug Control (Beijing, China).
Ammonium acetate, acetic acid, formic acid, acetonitrile, MgCl2,
Tris–HCl and other chemicals and solvents were analytical
reagents obtained from Sinopharm Chemical Regent Co. (Beijing,
China) or chromatographic grade obtained from Tedia, Co.
(Fairfield, OH, USA).
Construction of Human POR Variant cDNAs
Site-directed mutagenesis was performed using Site-directed
Mutagenesis Kit (Stratagene, Cambridge, UK) according to
manufacturer’s instructions. The template plasmid with cDNAs
encoding wild-type POR tagged with histidine (His6) has been
previously cloned into pFastBac1 in our laboratory. Primers used
in site-directed mutagenesis are listed in Table S1, and the
mutated condos have been underlined. We amplified the DNA
containing desired mutations by PCR, with initial denaturation at
94uC for 1 min followed by 32 cycles of denaturation at 94uC for
50 s, annealing at 60uC for 50 s, and extension at 72uC for 7 min
30 s. Final extension was done at 72uC for 7 min. After PCR
amplification, the full-length cDNAs were completely sequenced
to ensure that there were no extra mutations. The mutant POR
cDNAs were then subcloned into the BamH I and Xho I sites of
the donor vector pFastbac1. The names of six full-length POR
missense mutations (i.e., K49N, POR*25; A115V, POR*11;
Y181D, POR*8; S244C; A287P, POR*5; G413S) were classified
according to the Human CYPallele nomenclature committee
(http://www.cypalleles.ki.se/por.htm).
Heterologous Expression of CYP3A4, CYP2B6 and POR
Enzymes
The Bac-to-Bac baculovirus expression system was used for the
expression of CYP3A4, CYP2B6 and POR enzymes. All steps for
the production of recombinant proteins were carried out as
described previously [32]. To obtain the reconstructed bacmid
DNAs, each individual recombinant pFastbac-3A4, pFastBac-2B6
or the wild-type and mutant pFastBac-POR donor plasmids were
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contained the baculovirus DNA. The reconstructed bacmids were
then transfected into Sf9 cells to obtain the recombinant
baculovirus stock. All stocks were successively amplified to a final
titer of approximately 1.0610
8 pfu/ml. Sf9 insect cell were
obtained from Yangshengtang Company (Hainan, China) and
maintained at 27uC in Grace’s medium containing 10% FBS. Sf9
cells were co-infected by CYP3A4 or CYP2B6 with POR
recombinant baculovirus particles, and then Hemin stock solution
(2 mg/ml, prepared by dissolving hemin in 50% ethanol and
0.2MNaOH) was added to the culture medium for a final
concentration of 2 mg/ml. After incubation for 72 h, the infected
Sf9 cells were harvested, washed with ice-cold phosphate balanced
solution (PBS, pH7.4) and re-suspended in the lysis buffer
(100 mM K3PO4,1 mM EDTA, 0.1 mM PMSF and 20%
glycerol, pH7.4). The microsomes were prepared by centrifugation
at 90006g for 10 min at 4uC after sonication of cells to obtain the
supernatant which was then stored at 280uC until use.
Real-time PCR Analysis
The recombinant viral titers of CYP3A4, CYP2B6 and wild-
type or mutant PORs were identified using real-time PCR, it has
been previously demonstrated that there exists good agreement
between DNA copy number and virus titers [33]. Total virus
genome was extracted from 200 ml virus supernatant by Body
Fluid Viral DNA/RNA Kit (Axygen, Hangzhou, China). Total of
the viral DNA copy number was determined by quantification of
viral DNA molecules by real-time PCR according to the
manufacture’s instruction of SYBR Premix Ex Taq
Tm Kit
(Takara, Dalian, China). The primers ATGATCAACATGGGA-
GACTCCCACGTGG (forward) and CTAGCTCCACACGTC-
CAGGGAGTAGC (reverse) were used to detect the viral DNA.
Western Blot Analysis
Sf9 cells were harvested, and washed twice with cold PBS. Cell
pellets were lysed by sonication in the presence of protease
inhibitors and the total protein concentration was determined by
BCA protein assay kit. Twenty microgram of each protein sample
was resolved by 8% SDS-PAGE and electroblotted onto
nitrocellulose membranes (Bio-Rad, Mississauga, ON). The
membranes were blocked for 1 h at room temperature in PBS
containing 5% skim milk plus 0.1% Tween-20 (PBST) and was
incubated overnight at 4uC with monoclonal antibody against
histidine as primary antibody (1:3000 dilution), followed by
incubation with a secondary antibody (goat anti-mouse IgG-
HRP, 1:5000 dilution) for 1 h at room temperature. The blots
were detected with Immobilon Western chemiluminescent HRP
(horseradish peroxidase) substrate (Millipore) by a lumino image
analyzer, LAS-1000 plus (FujiFilm) according to the manufactur-
er’s instructions. The amount of POR in each microsomal fraction
was detected by western blotting, and the quantification of the
immunoblots was performed by measuring the scanned band
intensities using Quantity One-4.6.2 Software. [32]. In addition,
the content of CYP3A4 and CYP2B6 co-expressed with PORs in
the microsomal fractions of Sf9 cells was quantitated by CO-
difference spectra using a molar extinction coefficient of 91 mM
21
[34].
POR Activity Assay
POR activity assay was performed by the reduction of
cytochrome c in the presence of wild-type POR and mutants
POR respectively [35]. Each sample was assayed in 840 mL
reductase assay buffer (50 mM potassium phosphate, 0.1 mM
EDTA, 0.3 M KCl, pH7.4) supplemented with 100 mLo f
cytochrome c (0.4 mM), and 50 mg of POR protein in aerobic
conditions at 30uC. Following incubation, the reaction was
initiated by adding NADPH to the reaction mixture to obtain a
final concentration of 5 mM. The rate of reduction of cytochrome
c was monitored at 550 nm for 3 min against a blank sample
containing the reductase assay buffer only.
Enzymatic Activity of CYP3A4-POR and CYP2B6-POR
Microsomes of CYP3A4 and CYP2B6 co-expressed with wild-
type or mutant PORs were determined for their metabolic ability
for testosterone and bupropion respectively. Each sample was pre-
incubated for 5 min at 37uC in a total volume of assay buffer
(100 mL), which included 50 pmol of CYP3A4-POR or CYP2B6-
POR microsomes, 100 mM Tris-HCl (pH7.4), 15 mM MgCl2,
NADPH generating system resulting in a final concentration of 1
unit isocitrate dehydrogenase/ml and 5 mM isocitrate. Concen-
trations of testosterone or bupropion in the incubation mixtures
ranged from 20 mM to 400 or 20 mM to 800 mM for CYP3A4-
PORs or CYP2B6-PORs. The reaction mixture was started by
addition of NADPH/NADP
+ at final concentration of 1 mM and
terminated after 60 min by the addition of two volumes of ice-cold
acetonitrile. After incubation, the reaction mixture was centrifuged
at 16,0006g for 20 min to obtain the supernatant and pellet
protein. The supernatant (20 mL) was then assayed directly by
using HPLC (Agilent Technologies 1200 series). All chromato-
graphic separations were obtained using a Dikma Technologies’s,
Diamonsil C18 column (5 mm, 20064.6 mm). For detection of
testosterone, it was monitored at 244 nm by C18 column with
acetonitrile-water (53:47, v/v) as mobile phase, at a flow rate of
1.0 ml/min [36]. For detection of bupropion, it was monitored at
245 nm by C18 column with acetonitrile-KH2PO4 (0.01 mol/L,
0.1% triethylamine, pH 6.0) 40:60 (v/v) as mobile phase, at a flow
rate of 1.0 ml/min as reported elsewhere [37]. All the mobile
phases were vacuum filtered through a 0.22 mm membrane before
use. The corresponding amount of metabolites at various
concentrations of testosterone and bupropion were identified by
external standard method. Because the pure standards of the
hydroxytestosterone and hydroxybupropion were not commer-
cially available, we used their substrates as the standard stock
solution for the assay of their metabolites. The data was fitted with
Michaelis-Menten model using GraphPad Prism 5 software
(GraphPad Software, La Jolla, CA).
Statistical Analysis
Each experiment was performed at least three times and all data
has been presented as mean 6 S.D. The Vmax and apparent Km
values were determined using nonlinear regression analysis of
Michaelis-Menten model (GraphPad Prism 5, Vision 5.01,
GraphPad Software Inc.) Statistical analysis of data was carried
out using a one-way ANOVA followed by Holm-Sidak pairwise
multiple comparison test (Sigmaplot, Systat Software Inc). A
probability value of less than 0.01 and 0.05 (*p,0.01 and
*p,0.05) was accepted as a significant difference.
Results
Expression of the Recombinant CYP3A4-POR and
CYP2B6-POR Proteins in sf9 Insect Cells
In order to better understand the effects of polymorphic
variants of POR on CYPs, six different mutants POR were
heterologously co-expressed with CYP2B6 and CYP3A4 in sf9
insect cells and were compared with activity of wild-type.
Figures S1, S2, and S3 show the protein expression levels in sf9
insect cells after infection of various mutants of POR with
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protein band at 78, 54 or 56 kDa for POR, CYP3A4 or
CYP2B6 (respectively), and there were no appreciable differ-
ences observed among the protein expression levels of POR
mutants, CYP3A4, CYP2B6 and wild-type, indicating all the
different proteins were expressed uniformly by a site-directed
mutagenesis. In addition, protein expression was not observed in
the negative control group as shown in Fig.S1A-3A left panels
(please see supplementary data).
The amount of POR in each microsomal fractions were
quantitated by western blotting according to the published method
[32], while the microsomal concentrations in sf9 cells of CYP3A4
or CYP2B6 co-expressed with PORs were quantitated by CO-
induced difference spectra, as shown in Table 1 and Figure S4. In
addition, we have also determined the viral titers of CYP3A4,
CYP2B6, mutants POR and wild-type by real time-PCR, as
shown in Table S2. In our preliminary experiment, we have found
that the metabolic activities of CYP3A4 and CYP2B6 were much
higher at the ratio of 2:1 for CYPs to POR virus; thereby this ratio
was selected for subsequent experiments.
Enzymatic Activities of PORs
In order to understand the influences of mutations on POR
activity, the specific enzymatic activities of six POR mutants
were determined in vitro using reduction of Cytochrome c
system, as described in method. The changes in the activity of
each POR (i.e., six genetically-altered POR) in cells expressing
PORs alone or co-expressing with CYP3A4 (or CYP2B6) are
summarized in Table 2. Only a little amount of endogenous
POR activity was found in the cells transfected with vector
alone, while the enzyme activity (i.e., POR) was significantly
increased by infection of external wild-type human POR in cells
(Table 2). In addition, Sf9 cells infected with the virus of POR
mutants (e.g., Y181D, A287P), showed more than ,80%
inhibition of POR activity in comparison to the wild-type.
More interestingly, mutations by S244C and G413S variants
enhanced the enzyme activity of wild-type up to approximately
13% and 77% (respectively). Regarding to the remaining two
POR-mutants, namely, A115V and K49N, POR activity was
decreased to 69–85% as compared to the wild-type activity,
suggesting that the POR activities can be influenced by
mutations in the amino acid sequences of POR.
On the other hand, the efficiency of each POR activity (e.g.,
activities of PORs were calculated and expressed as a percentage
of the activity of wild-type POR) in cells co-expressing PORs with
CYP3A4 (or CYP2B6) was found to be similar to the cells
expressing PORs alone (Table 2), but activities of some of the
POR mutants intended to increase in sf9 cells co-expressing PORs
with CYP3A4 (or CYP2B6), suggesting that CYPs may alter the
POR activity.
Enzymatic Activities of CYP3A4-POR
We further sought to determine whether the six polymorphic
variants of POR can alter CYPs-mediated metabolic variations,
for which CYP3A4 and CYP2B6 were co-expressed with six POR-
mutants (respectively) in sf9 insect cells. Afterward, the metabolites
of testosterone (as a specific substrate for CYP3A4) and bupropion
(as a specific substrate for CYP2B6) were determined to establish
the changes in the activities of CYP3A4 and CYP2B6. The
metabolic products were determined by HPLC with their
authentic standards (i.e., testosterone and bupropion). Figure 1
shows the metabolite of testosterone by CYP3A4 after being co-
expressed with six different POR mutants and the kinetic
parameters are summarized in Table 3. Surprisingly, some of
the six polymorphic variants exhibited significantly altered
activities of CYP3A4. In particular, activity of CYP3A4 was
completely inhibited by the co-expression of Y181D and A287P
(i.e., CYP3A4-POR (Y181D) and (A287P)) as in Table 3, and no
metabolic products for testosterone (i.e., hydroxylation of testos-
terone) were found. These results strongly supported that CYPs
functional partners may indeed influence the CYP-mediated
metabolic activities.
On contrary, the remaining three variants, K49N, A115V and
G413S of POR showed a significant increase in the catalytic
efficiencies of CYP3A4-POR, which was judged by the ratios of
Vmax/Km (CLint) when compared with wild-type. In particular,
CYP3A4-POR (G413S) exhibited the highest changes in the Km
and Vmax (1.3-folds) values compared to wild-type, and increased
the catalytic efficiency (CLint) up to 65% of wild-type. Moreover,
CLint values of CYP3A4-POR (K49N) and CYP3A4-POR
(A115V) were calculated to increase up to 31% and 36% of
wild-type. Additionally, mutant S244C of POR also increased the
activity of CYP3A4, but it was much less than that of K49N,
A115V and G413S, as shown in Table 3.
Enzymatic Activities of CYP2B6-POR
Regarding the impact of six POR genetic mutations on catalytic
activities of CYP2B6 (i.e., CYP2B6-POR) with bupropion (as a
specific substrate for CYP2B6), we found that the influences of
POR genetic mutations on catalytic activities of CYP2B6 were
different as compared to that of CYP3A4, as shown in Figure 2.
More interestingly, regarding to the metabolite of bupropion by
CYP2B6 in sf9 cells co-expressed with K49N (i.e., CYP2B6-POR
(K49N)), the Vmax was significantly reduced to 58% of the wild-
type, and the catalytic efficiencies were also reduced approxi-
mately up till 30%, while mutant K49N (i.e., CYP3A4-POR
(K49N)) enhanced the catalytic efficiency of CYP3A4 up to 31%
of wild-type, as shown in Figure 2 and Table 3.
With respect to A115V and G413S, the activities of CYP2B6
were not affected significantly by co-expressing with these two
mutants (Table 3), while they increased the activity of CYP3A4
significantly as described above. In addition, although Y181D and
A287P reduced the activities of CYP2B6 to approximately 70% of
wild-type, however, activities of CYP3A4 were completely
inhibited by the two mutants (Table 3).
Table 1. The content of CYP3A4 and CYP2B6 co-expressed
with wild-type or six POR mutants in sf9 microsomal fractions
were determined on the basis of reduced CO-difference
spectrum.
Protein
CYP3A4 (pmol/mg
protein)
CYP2B6 (pmol/mg
protein)
WT 56.464.1 44.361.1
K49N 69.063.6 61.261.7
A115V 49.162.8 46.962.3
Y181D 74.166.7 49.264.5
S244C 48.362.0 36.861.8
A287P 59.563.3 54.563.8
G413S 43.962.1 56.961.9
doi:10.1371/journal.pone.0038495.t001
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Pharmacogenetics has been used recently to establish correla-
tions between genetic polymorphisms and variations in drug
efficacy, which might contribute to the development of personal-
ized medicine in the near future. Additionally, an individual’s
genetic makeup and genetic polymorphism may lead to optimi-
zation of therapeutic strategies resulting in maximum therapeutic
efficiency and minimal adverse drug reactions [38,39].
Cytochrome P450 oxidoreductase (POR) is known to play a
critical role in delivering electrons to all microsomal P450 enzymes
and many of the redox system [10]. Moreover, animal experi-
ments have also indicated that the POR may contribute to the
embryonic development, because the POR knockdown resulted in
an early embryonic lethality. Recently, it has been reported that
the genetic polymorphisms of POR had definitely affected
endocrinology, pharmacology and as well as the developmental
biology [17,18]. Thus, the function and activities of POR
(including genetic polymorphisms) should be clearly identified.
The human POR variants were recently expressed by using
truncated cDNAs in bacterial system (prokaryocytes) to evaluate
the effects of the POR on drug metabolism. However, in this
system the expressed POR proteins were found to lack many
amino acid residues (for example, 27 or 46 N-terminal amino
acid residues) [29,30,31,35,40,41,42]. Recent studies have
confirmed that the hydrophobic N-terminal sequence of
NADPH cytochrome P450 reductase (residues 1–46) not only
participate directly in orientation in the endoplasmic reticulum
but also play a key role in cytochrome P450 interaction. It has
been recently reported that the substantial differences were
observed in the electron-transfer abilities between the full-length
POR variants and N (27)-deleted form in E.coli, suggesting that
the full-length POR variants may be more suitable for
evaluating the human POR-variants [26,43,44]. In the present
study, the wild-type and six polymorphic variants of POR with
full-length gene were co-expressed in Sf9 insect cells (i.e.,
eukaryotic cell), which presented to be a more suitable
physiological model for the evaluation of human variants. In
Table 2. The reductive activity of wild-type and variant POR expressed alone and the activity of POR co-expressed with CYP3A4 or
CYP2B6 in sf9 was estimated by NADPH-dependent Cytochrome c reduction.
Protein POR (mmol/min/mg protein) CYP3A4-POR (mmol/min/mg protein) CYP2B6-POR (mmol/min/mg protein)
Vector 0.0460.002* (1%) – –
Wild-type 3.960.32
# (100%) 4.560.21 (100%) 4.760.15 (100%)
K49N 3.360.21
# (85%) 3.560.29 (78%) 4.560.25 (97%)
A115V 2.760.15
#* (69%) 3.160.13 (69%)* 4.360.37 (93%)
Y181D 0.560.07
#* (13%) 2.360.15 (50%)* 2.660.11 (56%)*
S244C 4.460.35
# (113%) 5.860.31 (130%) 5.360.18 (113%)
A287P 0.860.06
#* (21%) 2.560.13 (54%)* 2.960.43 (63%)*
G413S 6.960.54
#* (177%) 8.760.41 (193%)* 9.960.43 (211%)*
The activity of each POR mutant was calculated and expressed as a percentage of the activity of wild-type POR, arbitrarily set at 100%.
The values mean 6S.D. of three independent experiments.
#: p,0.01 in comparison with the vector control cells.
*: p,0.01 in comparison with the cells expressing wild-type (WT) POR.
doi:10.1371/journal.pone.0038495.t002
Figure 1. Determination of enzymatic activities of CYP3A4-PORs. Kinetics for the formation of hydroxytestosterone was determined by
incubation of testosterone with CYP3A4–PORs, as described in method. Data are depicted as mean6S.D. (n=3). The insert graphs show the
Lineweaver–Burk plot of the data.
doi:10.1371/journal.pone.0038495.g001
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cells to be almost identical, we quantified each virus DNA copy
number of six human genetic variations of POR (i.e., A115V,
Y181D, K49N, S244C, A287P and G413S) or CYP3A4/
CYP2B6 by real-time PCR (Table S2). Furthermore, the
amount of POR in each microsomal fraction was quantitated
by western blotting, while the contents of CYP3A4 and
CYP2B6 in the microsomal fractions of Sf9 cells were quan-
titated by CO-difference spectra (Figs. S1, S2, S3, and S4).
In order to assess the activities of POR variants, each POR was
expressed independently or co-expressed with CYP3A4 or
CYP2B6 in sf9 cells. The activities of POR variants were
determined by measuring reduction of Cyt c. Interestingly, the
mutants Y181D and A287P in POR strongly reduced the activity
to approximately 20% of wild-type, while S244C and G413S
enhanced the POR activity up to 13% and 77% respectively
compared with wild-type (Table 2), suggesting that the POR
mutation could influence the original activity of wild-type. In
addition, Y181D and A287P reduced the activity up to
approximately 50% of the wild-type in cell co-expressing PORs
with CYPs, and activities were also significantly increased when
compared with cells expressing PORs alone (Table 2). This
disparity in the results may be probably due to the protein-protein
interactions between two different approaches, and further work is
needed to confirm this conclusion.
Additionally, we determined the Km and Vmax values for two
specific substrates (i.e., testosterone and bupropion) by CYP3A4-
POR and CYP2B6-POR. The activity of CYP3A4 was completely
inhibited after co-expressing with Y181D and A287P when
compared with the wild-type (Table 3), this result was also found
to be consistent with the early study where POR variant, Y181D
located in FMN binding domain resulted in inhibition of CYP3A4
Table 3. Km and Vmax values for CYP3A4 and CYP2B6 enzymes with different mutants of POR were determined by their specific
substrates testosterone and bupropion.
POR CYP3A4 - Testosterone CYP2B6 – Bupropion
Km (nM/min/pmol) Vmax (% of WT) Clint (mM) Km (nM/min/pmol) Vmax (% of WT) Clint (mM)
WT 236.7610.3 13.7060.88 0.05860.0039 (100) 388.8620.02 10.5960.54 0.02760.0027 (100)
K49N 197.769.0* 15.0860.31 0.07660.0040 (131)* 311.1612.13* 6.1260.43* 0.02060.0017 (74)
#
A115V 211.8613.8 16.6560.53* 0.07960.0058 (136)* 294.6626.19* 7.4460.30* 0.02560.0024 (93)
Y181D – – – 369.6.610.96 7.1060.26* 0.01960.0015 (70)
#
S244C 219.7622.6 14.6560.74 0.06760.0091 (115) 316.5613.37* 9.9560.44 0.03160.0018 (115)
A287P – – – 475.1624.91* 9.2860.65 0.02060.0015 (74)
#
G413S 183.3613.3* 17.5760.58* 0.09660.0044(165)* 299.7613.07* 6.6560.36* 0.02260.0019 (81)
The ratio of Vmax to Km was used as an index of catalytic efficiency; the activity of each POR mutant co-expressed with CYPs was calculated and expressed as a
percentage of the activity of wild-type POR, arbitrarily set at 100%.
The data were represented as mean 6 S.D. of three independent experiments.
CLint=Vmax/Km.
*: p,0.01 in comparison with the cells expressing wild-type (WT) POR.
#: p,0.05 in comparison with the cells expressing wild-type (WT) POR.
Dash (–) indicates not detectable.
doi:10.1371/journal.pone.0038495.t003
Figure 2. Determination of enzymatic activities of CYP2B6-PORs. Kinetics for the formation of hydroxybupropion was determined by
incubation of bupropion with CYP2B6-PORs, as described in Method. Data are depicted as mean6S.D. (n=3). The insert graphs show the
Lineweaver–Burk plot of the data.
doi:10.1371/journal.pone.0038495.g002
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were also observed in P450 based assay, where the activities of
CYPs (e.g., CYP17A1, CYP2C19, CYP1A2) were completely
inhibited by mutation of FMN binding domain at POR (i.e.,
Y181D) [29,46,47,48]. However, in the present study, differently
from the former observations, the activity of CYP2B6 was not
affected by POR mutants (i.e., Y181D and A287P) (Fig.2 and
Table 3). Dhir et al (2007) reported that A287P of POR showed
significantly lower activities in supporting 17, 20 lyase, CYP1A2
and CYP2C19, and had similar activities as compared to wild-type
for CYP19A1 and CYP21A2, suggesting that A287P mutation
may show variable effects when co-working with different redox
partners [31,47,48]. Flu ¨ck et al. (2010) has reported that 60% of
CYP3A4 activity was lost by A287P mutant of POR with
BOMCC, but the CYP3A4 activity on testosterone was completely
lost by A287P mutant in our current study, suggesting that the
impact of POR variants on the catalytic activity of CYP3A4 is
substrate-specific.
Regarding the K49N mutation which was localized in
transmembrane domain, the variation of CYP3A4-POR (K49N)
for Vmax/Km values were increased up to 31% of wild-type, while
it decreased in CYP2B6-POR (K49N) to 74% of wild-type
(Table 3). Furthermore, POR mutant A115V and G413S
enhanced the catalytic activities of CYP3A4 to 36% and 65%
(respectively) despite of the metabolic activity of CYP2B6 to
bupropion which was not significantly influenced by these two
mutants (Table 3). S244C mutant is located in a highly flexible
hinge region which is the connecting domain combining FAD and
FMN together to facilitate the electron transfer. In fact, S244C
resulted in increasing the catalytic efficiency of CYP3A4 and
CYP2B6 (approximately 15%) in the present study, but according
to other literature it reduced the catalytic efficiency of CYP17A1
and CYP21A2 up to more than 70% [47]. Regarding to the above
information, it can be revealed that the same mutant in POR is
able to make diverse impacts on the catalytic efficiency when co-
working with different CYP redox partners.
To date, more than 50 microsomal P450 enzymes and 40
mutants POR have been found in human [7,21,22]. Therefore,
each POR variants will require testing with each CYP superfamily
member and other drug metabolizing P450s to assess their effects.
To make the CYP-mediated drug metabolism affected by POR
mutations more clearly, additional studies covering different other
types of CYPs are required to take either in vitro or in vivo drug
clearance tests. In summary, we suggested that the POR-mutant
patients should be carefully monitored for the activity of CYP3A4
and CYP2B6 for the prescribed medication to obtain maximum
therapeutic efficiency and minimal adverse drug reactions.
Therefore, our present study would be helpful to set up a database
about the influence of POR genetic polymorphisms as a biomarker
to predict the POR-involved metabolic activity of clinical drugs.
Supporting Information
Figure S1 Immunoblot analysis of wild type and six
mutant POR microsomal proteins in Sf9 cells. (A) The
position of POR proteins was detected at 78 kDa by Western blot.
N: negative. W: wild type. (B) The relative expression levels of wild
type and mutants POR in Sf9cells were quantified with Quantity
One Software. The results are indicated as mean 6 S.D. of three
independent experiments.
(TIF)
Figure S2 Immunoblot analysis of CYP3A4 microsomal
proteins co-expressed with wild type or six mutants
POR in Sf9 cells. (A) The position of CYP3A4 proteins were
detected at 54 kDa by Western blot after infections with wild type
or mutants POR, as described in Methods. (-): negative. WT: wild
type. (B) The relative expression levels of CYP3A4 proteins in
POR-infected Sf9 cells were quantified with Quantity One
Software. The results are indicated as mean 6 S.D. of three
independent experiments.
(TIF)
Figure S3 Immunoblot analysis of CYP2B6 microsomal
proteins co-expressed with wild type or six mutants
PORsSf9 cells. (A) The position of CYP2B6 proteins was
detected at 56 kDa by Western blot after infections with wild type
or mutants POR, as described in Methods. (-): negative. WT: wild
type. (B) The relative expression levels of CYP2B6 proteins in
POR-infected Sf9 cells were quantified with Quantity One
Software. The results are indicated as mean 6 S.D. of three
independent experiments.
(TIF)
Figure S4 CO-difference spectrum of the expressed
CYP3A4 (A) and CYP2B6 (B). Content was determined from
the carbon monoxide difference spectrum and the molar
absorption coefficient for cytochrome P450.
(TIF)
Table S1 PCR primers used for site-directed mutagen-
esis of POR cDNAs.
(DOCX)
Table S2 Real-time PCR titration results for CYP3A4,
CYP2B6 and wild type or mutant PORs.
(DOCX)
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